Mild Cognitive Impairment Market Research Report - Global Forecast till 2030

Mild Cognitive Impairment Market Research Report: Information by Disease Type (Amnestic MCI and Non-Amnestic MCI), by Age (Child, Adult, and Geriatric), by Indications (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and Other Indications) by Treatment (Medication [Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors], Therapy [Cognitive Stimulation Therapy and Cognitive Behavioural Therapy (CBT)]), by Region (North America, Europe,

ID: MRFR/HC/9432-HCR | 120 Pages | Published By Rahul Gotadki on April 2023         

Mild Cognitive Impairment Market

Mild cognitive impairment market size is projected to be worth USD 2.96 billion by 2030, registering a CAGR of 5.30% during the forecast period 2022 - 2030

Key Players
Companies Profiled   Pfizer Inc. (US)   Hoffman La Roche Ltd (Switzerland)   Novartis AG (Switzerland)   Accord UK Ltd (UK)   Reddy’s laboratories Ltd (India)   Hikma Pharmaceuticals PLC (UK)   Sun Pharmaceuticals ltd (India)   Johnson & Johnson Services Inc. (US)   Teva Pharmaceutical Industries Ltd. (Israel)
Market Driving Forces   Increasing geriatric population   Rising awareness about mild cognitive impairment
Request a Free Sample

Mild Cognitive Impairment Market Forecast

The global mild cognitive impairment market size is projected to be worth USD 2.96 billion by 2030, registering a CAGR of 5.30% during the forecast period (2022 - 2030)

Mild cognitive impairment (MCI) is a stage of memory loss or other cognitive skill loss (such as language or visual/spatial perception) in people who can still perform most everyday tasks independently. MCI can develop from a variety of causes, and those who have it may acquire dementia. MCI is a stage on the illness continuum for neurodegenerative disorders such as Alzheimer's. MCI can recover to normal cognition or remain stable in some people. The Dementia market has been segmented based on disease type, age, Indications, treatment, and region. The market is driven by factors like the increasing geriatric population globally and rising awareness about mild cognitive impairment. However, the unavailability of specific treatment could hamper the growth of the mild cognitive impairment market.

Mild Cognitive Impairment Market COVID-19 Analysis

COVID-19 has put significant strain on dementia health and social care systems across the world. As a result, services, assistance for people suffering from MCI have been reduced due to restrictions set to curb the spread of the virus. The pandemic has also caused delays in the provision of mental health services and increased the need for digital intervention. Such consequences have boosted the need for efficient remote care for mild cognitive impairment (Dementia) to compensate for the pandemic's disruptions.

According to the National Library of Medicine, the dementia population is at significant risk of getting COVID-19 infection because cognitive problems make it hard to follow the safety precautions designed to limit viral transmission. As a result, the pandemic had a detrimental impact on the market's growth potential for moderate cognitive impairment (Dementia).

Dementia Market Dynamics


  • Increasing geriatric population

    • The increasing prevalence geriatric population globally is a major driver of the demand for the mild cognitive impairment market. For instance, according to the National Institute on Aging, persons with mild cognitive impairment are more likely to develop Hypertension or comparable dementia than people not having it. Over a year, an estimated 10 to 20% of people 65 and older with mild cognitive impairment acquire dementia.

    • Furthermore, according to World Health Organization, in 2021, almost 7 million people ages 65 or older had dementia and more than 55 million people with dementia worldwide has negatively impacted their behavior. However, Women, those over the age of 85, and racial minorities are at a greater risk of acquiring dementia. According to the World Health Organization, more than 7 million people aged 65 and more will develop dementia by 2022. Moreover, more than 9 million Americans may get dementia by 2030, with the number increasing to almost 12 million by 2040. Hence, the increasing number increasing geriatric population and such disorders is driving the adoption rate of Dementia market.

  • Rising awareness about mild cognitive impairment

Market Restraints

  • Unavailability of specific treatment

    • In contrast to dementia, no drugs are presently licensed for the treatment of MCI. As MCI is related to dementia. It was initially hoped that the Alzheimer drugs donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) would alleviate MCI symptoms or slow the progression to dementia. However, numerous trials of these drugs have been conducted, with no clear benefit to patients. progression.

    • There are no authorized pharmacological therapies for mild cognitive impairment of any origin, and pharmacological treatments are of little utility in mild dementia caused by Alzheimer's disease. However, treatments for reversible causes of MCI such as blood pressure, sleep apnea, and certain medications are tried. As a result, the lack of drugs for the treatment of cognitive impairment therapy may hamper mild cognitive impairment market growth.

Market Opportunities

  • Promoting patient mental health programs

    • Mental health interventions increase overall well-being and are available in environments where individuals live, work, study, and prosper. These include mental health programs in schools and workplaces, early childhood treatments, social support and community participation, women's empowerment, anti-discrimination policies, and other interventions addressing the social determinants of mental health.

    • Cognitive therapies that promote cognitive health are classified as cognitive stimulation or cognitive training. Cognitive stimulation entails a wide range of activities, usually done in a group context, to improve overall cognitive and social functioning. Cognitive stimulation programs include experience corps and senior odyssey (University of Illinois, IL, USA). Each has found that program participants have better cognitive functioning than control individuals. Moreover, the Emory Brain Health Center (US) has launched a revolutionary new programme to combat early memory declines, a condition that affects up to 20% of Americans over the age of 65 and is expected to double to 88.5 million by 2050. Furthermore, in order to reduce mild cognitive impairment, the programme will include clinical care, patient and caregiver support, research, and patient participation in their health and wellness. Such new programs are expected to drive mild cognitive impairment market growth in the future

Value Chain Analysis

The value chain analysis for the market comprises four major components, which start with the research and product development stage where the new techniques and research are undertaken to make the products better and unique, followed by the manufacturing, in this stage, the product strategies are ready, and the manufacturing process of the product starts, distribution & sales where distribution includes intermediaries, direct selling, online channels, and others. For this, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing    It ends with post-sales monitoring, many companies undertake numerous surveys to get post-sale feedback in order to ascertain the advantages and disadvantages of genetic testing.

Dementia Market Segment Overview

By Disease Type

  • Amnestic MCI

Amnestic MCI is a condition where people have memory impairments that are worse than average for their age and educational level but not severe enough to affect daily life. People who have amnestic MCI may begin to forget important information that they would have previously easily recalled, such as appointments, conversations, and recent events.

Amnestic MCI held the largest share in the Dementia market in 2021 due to the increase in the older population across the globe.

Non-Amnestic MCI

Non-amnestic MCI affects thinking skills other than memory, including the ability to make sound decisions, judge the time or sequence of steps needed to complete a complex task, or visual perception. Furthermore, those with non-amnestic MCI are more likely to develop vascular dementia, frontotemporal dementia, or dementia with lewy bodies.

By Age

  • Child

Childhood MCI is a mental disorder, since it develops as a variety of symptoms, this condition cannot be classified as a disease. Moreover, cognitive deficiencies (intellectual disability) appear in children as substantial limitations in their abilities to learn and perform.

  • Adult

Mental impairment in older adults refers to a person's concern about or difficulties with thinking, memory, concentration, and other brain functions that exceeds what is normally expected with ageing. Additionally, adult-onset conditions such as: Brain or spinal cord damage, vitamin deficiency, or drug or alcohol misuse. Furthermore, Subjective cognitive decline (SCD) affects 11.1 % of individuals, or 1 in 9, and mild memory loss is rather common, affecting between 10% and 20% of older persons in the United States.

  • Geriatric

Mild cognitive impairment (MCI) is a prevalent problem among the elderly. It is distinguished by a decline in memory, attention, and cognitive function that exceeds what would be predicted based on age and educational level. MCI has no substantial impact on people's daily activities.

The geriatric segment held the largest market share in 2021 due to a surge in vulnerable older people population across the globe.

By Indications

  • Lewy Body Dementia

Lewy body dementia (LBD) is one of the most frequent kinds of dementia. It mainly affects adults over the age of 50. People with LBD frequently act out their dreams and make violent gestures while sleeping. It is known as REM sleep behavior disorder. It is sometimes the first indication that someone has LBD. According to the Lewy Body Dementia Association, more than one million persons in the U.S have Lewy body dementia.

  • Parkinson's Disease Dementia

Parkinson's disease dementia (PDD) is a loss in thinking and reasoning capacity that occurs at least a year after diagnosis in certain Parkinson's patients. Parkinson's disease is caused by alterations in the brain's movement-related area, which causes early symptoms such as tremors and shakiness, muscular rigidity, a shuffling stride, stooped posture, trouble commencing movement, and a lack of facial expression.

  • Alzheimer’s Disease Dementia

Alzheimer's disease is the most prevalent kind of dementia and a degenerative brain illness. It currently affects an estimated 6.2 million Americans aged 65 and older. If no medical advances are achieved to prevent, slow, or cure Alzheimer's disease, this amount might climb to 13.8 million by 2060. According to official death certificates, Alzheimer's disease was the sixth-leading cause of death in the United States in 2019, and the fifth-leading cause of death among Americans 65 and over.

This segment held the largest share in 2021, owning to the growing number of people living with Alzheimer’s dementia across the globe.

  • Vascular Dementia

Vascular dementia is the second most frequent kind of dementia, accounting for 17-30% of cases. It is frequently caused by a blood artery obstruction, such as in a stroke, or by a brain injury that results in patches of dead tissue or bleeding. Vascular dementia alone affects 5% to 10% of dementia sufferers. Despite its prevalence, many professionals believe that vascular dementia, like Alzheimer's disease, is underdiagnosed. Furthermore, like Alzheimer's disease, vascular dementia worsens with age, contributing to the global dementia epidemic in ageing populations.

  • Other Indications

Other indications comprise mixed dementia, Huntington's disease, limb-predominant age-related TDP-43 encephalopathy, and chronic traumatic encephalopathy.

By Treatment

  • Medication

Based on treatment type, the mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. Medication segment held the largest share in 2021. This is due to its immediate and effective impact on MCI symptoms. Medicine has been further categorized into cholinesterase inhibitors, benzodiazepines, glutamate inhibitors, antihistamines, Mao inhibitors, and proton pump inhibitors.

  •  Therapy

Based on therapy type, the Mild Cognitive Impairment Market is segmented into Cognitive Stimulation Therapy, Cognitive Behavioral Therapy (CBT). Cognitive Stimulation Therapy (CST) is a well-known therapy for people with mild to severe dementia. CST therapy can be given by anyone who works with dementia patients, including caregivers, psychologists, occupational therapists, and nurses. CST sessions can take place in a range of locations, such as nursing homes, hospitals, and daycare facilities.  The UK Government's NICE dementia advice also suggests group cognitive stimulation therapy for patients with mild to severe dementia. CST is widely used in the UK and throughout the world, with initiatives in at least 35 countries.

Mild Cognitive Impairment Market Regional Analysis

The Mild Cognitive Impairment Market based on the region has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The rising burden of cognitive impairment and increasing geriatric population is one of the major factors driving the market growth.  The growth Dementia market can be attributed to factors such as the increasing prevalence of mild cognitive impairment, rising geriatric population, and growing awareness about available therapies for mild cognitive impairment.

North America

The increase in the older patient population, ongoing research to find the effective cure are fueling the growth of the North American Mild Cognitive Impairment Market.

In the US, more than 16 million people have cognitive impairment. Alzheimer's disease, the most well-known kind of cognitive impairment, affects an estimated 5.1 million Americans aged 65 and older; this is expected to climb to 13.5 million by 2050.  Such a higher prevalence of the disease is anticipated to bolster the demand for mild cognitive impairment (dementia) drugs among the patient population over the coming years. Furthermore, a number of market participants are working to implement strategic developments that will aid in market expansion. As an instance, the US Food and Drug Administration approved Aduhelm (aducanumab) to treat Alzheimer's disease in June 2021, which is expected to show some effect  MCI. As a result of the developments, as well as the disease's increasing burden, the regional market is expected to grow significantly over the forecast period.

Dementia Market Competitive Landscape

The industry players are adopting several business strategies to increase their market presence. They are significantly investing in R&D activities to expand their product portfolio, further driving the Mild Cognitive Impairment Market. In addition, the market players are adopting several strategic initiatives such as new product launches, contractual agreements, mergers & acquisitions, increasing investments, and partnering with other players to expand their global footprint.

Some key players in the market are Pfizer Inc. (US), Novartis AG (Switzerland), and F. Hoffman La Roche Ltd (Switzerland). Pfizer, Inc. (Pfizer) is one of the leading research-based biopharmaceutical organizations. The company develops medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare worldwide. It operates in Germany, France, Greece, South Korea, Mexico, Russia, the Netherlands, India, Poland, Turkey, Israel, and China. The company has R&D platforms in biosimilars, gene therapy, precision medicines, and medicinal sciences. Its products serve key therapeutic areas, such as oncology, internal medicine, inflammation and immunology, rare diseases, and vaccines, along with contract manufacturing capabilities. Pfizer Centre One, a part of Pfizer, focuses on custom APIs, sterile injectables, and highly potent oral solid dosage forms.  Product launcehs such as The FDA approval of Novartis AG's (Switzerland) Rivastigmine (Exelon) for mild-to-moderate Alzheimer’s disease and mild-to-moderate dementia associated with Parkinson's disease in June 2019 are also driving market grwoth.

List of companies covered in this report:

  • Pfizer Inc. (US)

  • Hoffman La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Accord UK Ltd (UK)

  • Reddy’s laboratories Ltd (India)

  • Hikma Pharmaceuticals PLC (UK)

  • Sun Pharmaceuticals ltd (India)

  • Johnson & Johnson Services, Inc. (US)

  • Teva Pharmaceutical Industries Ltd., (Israel)

  • Takeda Pharmaceutical Company Limited (US)

Mild Cognitive Impairment Market Recent Developments

  • In March 2022, Teva Pharmaceutical Industries Ltd. launched generic revlimid (lenalidomide capsules) in the U.S.

  • In July 2022, Roche's Elecsys Amyloid Plasma Panel has been given FDA breakthrough device designation to aid in the early detection of Alzheimer’s disease.

  • In July 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Genentech, Inc. (US) has entered into a collaboration agreement with UCB S.A. (Belgium) to develop and commercialize an antibody therapy for Alzheimer’s disease.

  • In June 2019, The FDA approved Novartis AG's (US) Rivastigmine (Exelon) for mild-to-moderate Alzheimer’s disease and mild-to-moderate dementia associated with Parkinson’s disease.

  • In January 2018, Takeda Pharmaceutical Company Limited (US) collaborated with Denali therapeutics (US) to develop and commercialize therapies for neurodegenerative diseases.

Mild Cognitive Impairment Market Report Overview

The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.

Study Objectives

  • To provide a detailed analysis of the market structure and forecast for the next seven years of the various segments and sub-segments of the Mild Cognitive Impairment Market

  • To provide insights about factors affecting the market growth

  • To analyze the Dementia market based on various factors- price analysis, supply chain analysis, Porter's five force analysis, etc.

  • To provide historical and forecast revenues of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia-Pacific, and the Rest of the World

  • To provide country-level analysis of the market with respect to the current market size and future prospective

  • To provide country-level analysis of the market for segments by disease type, age, indications, and treatment

  • To provide strategic profiling of key players in the market, comprehensively analyze their core competencies, and draw a competitive market landscape

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers & acquisitions, new product developments, and R&D in the Mild Cognitive Impairment Market

Market Segmentation:

Global Mild Cognitive Impairment Market, By Disease Type

  • Amnestic MCI

  • Non-Amnestic MCI

Global Dementia market, By Age

  • Child

  • Adult

  • Geriatric

Global Mild Cognitive Impairment Market, By Indications

  • Lewy Body Dementia

  • Parkinson's Disease Dementia

  • Alzheimer’s Disease Dementia

  • Vascular Dementia

  • Other Indications

Global Mild Cognitive Impairment Market, By Treatment

  • Medication

    • Cholinesterase Inhibitors

    • Benzodiazepines

    • Glutamate Inhibitors

    • Antihistamines

    • Mao Inhibitors

    • Proton Pump Inhibitors

  • Therapy

    • Cognitive Stimulation Therapy

    • Cognitive Behavioural Therapy (CBT)

Global Mild Cognitive Impairment Market, By Region

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Intended Audience

  • Mild cognitive impairment product manufacturers and suppliers

  • Primary care providers

  • Physicians

  • Public health professionals

  • Health educators

  • Nurse practitioners

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 2.96 Billion by 2030
  CAGR   5.30%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018 & 2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Disease Type, Age, Indications, Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   • Pfizer Inc. (US) • F. Hoffman La Roche Ltd (Switzerland) • Novartis AG (Switzerland) • Accord UK Ltd (UK) • Dr. Reddy’s laboratories Ltd (India) • Hikma Pharmaceuticals PLC (UK) • Sun Pharmaceuticals ltd (India) • Johnson & Johnson Services, Inc. (US) • Teva Pharmaceutical Industries Ltd., (Israel) • Takeda Pharmaceutical Company Limited (US)
  Key Market Opportunities   Promoting patient mental health programs
  Key Market Drivers   • Increasing geriatric population • Rising awareness about mild cognitive impairment

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The global mild cognitive impairment market size is expected to reach USD 2.96 billion at CAGR of 5.30% during the forecast period (2022 - 2030)

Pfizer Inc. (US), F. Hoffman La Roche Ltd (Switzerland), Novartis AG (Switzerland), Accord UK Ltd (UK), Dr. Reddy’s laboratories Ltd (India), Hikma Pharmaceuticals PLC (UK), Sun Pharmaceuticals ltd (India), Johnson & Johnson Services, Inc., (US), Teva Pharmaceutical Industries Ltd., (Israel), and Takeda Pharmaceutical Company Limited (US) are the leading players in the market of Mild Cognitive Impairment.

North America holds the largest share in the global market of Mild Cognitive Impairment.

Increasing geriatric population and Rising awareness about mild cognitive impairment are the key factors driving the market of Mild Cognitive Impairment.

Unavailability of specific treatment may act as market deterrents of Mild Cognitive Impairment